The ESCMID Study Group for Non-Traditional Antibacterial Therapy (ESGNTA) brings together professionals from various expertise dedicated to advancing the use of bacteriophages and other new non-traditional therapeutic approaches to treat infectious diseases. Their mission includes:
ESGNTA Newsletter, Spring 2024, April 2024
ESGNTA Newsletter, Spring 2024, March 2024
ESGNTA Newsletter, Winter 2023, February 2023
ESGNTA Newsletter, Spring 2023, April 2023
ESGNTA Newsletter, Summer 2023, August 2023
ESGNTA Newsletter, Autumn 2023, November 2023
Phages and phage-borne enzymes as new antibacterial agents.
McCallin S, Drulis-Kawa Z, Ferry T, Pirnay JP, Nir-Paz R. Clin Microbiol Infect. 2023;20:S1198-743X(23)00528-1.
Personalized Phage Therapy: Basic Principles of monitoring and treatment: Supplement 5 1 Nov 2023
Nir-Paz R, Iredell J, Suh G, Fabijan AP. Clinical Infectious Diseases, Vol 77, Issue Supplement 5, 1 November 2023.
Global Clinical Phage Rounds 8
Lessons learned (so far) from treating patients with phage therapy for antibiotic-resistant bacterial infections
Global Clinical Phage Rounds 7
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter
Global Clinical Phage Rounds 6
The French Experience
Global Clinical Phage Rounds 5
Case Discussion – How long is enough: duration of phage therapy for NTM infections in three Australian patients?
Global Clinical Phage Rounds 4
Belgian Published cases
Global Clinical Phage Rounds 3
Case Discussion – Urgent cases on Mycobacterium
Global Clinical Phage Rounds 2
Case Discussion – Renal transplant and recurrent UTIs
ESGNTA as part of the VOM2023 conference
7 July 2023, The George Eliava Institute of Bacteriophages, Tbilisi, Georgia Congress
If you have questions or comments for our study group, we warmly invite you to contact us!